Fig. 2: WIgGWAM identifies both symmetric and asymmetric IgG glycoforms.
From: Asymmetrically glycosylated IgG1 antibodies are universal and drive human disease
a After WIgGWAM, a portion of the purified Fcs are treated with EndoS2 to determine fucosylation levels, the other portion of Fcs is analyzed with or without exoglycosidases and filtered according to a 20% of maximum peak height cutoff. Created in BioRender. D, J. (2025) https://BioRender.com/lybz9tn. b–f Deconvoluted intact LC/MS spectrum of Fcs purified with WIgGWAM from a healthy individual human plasma sample b treated with EndoS2. The dotted lines annotate the masses that correspond to the bifucosylated, monofucosylated, and afucosylated mass of the nG1m1 Fc allele c with no enzymes added. The dotted lines annotate Fc-linked glycoforms whose peak heights were at least greater than 20% of maximum peak height d with no enzymes added. The dotted lines annotate Fc-linked glycoforms whose peak heights were less than 20% of maximum peak height e treated with an exosialidase. The dotted lines annotate Fc-linked glycoforms whose peak heights were at least greater than 20% of maximum peak height f treated with an exogalactosidase. The dotted lines annotate Fc-linked glycoforms whose peak heights were at least greater than 20% of the maximum peak height. For all intact LC/MS deconvoluted spectra, the highest peak was normalized to 100. Source data are provided as a Source Data file.
